Breast cancer prognosis associated with oncometabolite accumulation

The metabolic profile of cancer cells can be used to develop therapies and identify biomarkers associated with cancer outcome. In this issue of the Journal of Clinical Investigation Stefan Ambs and colleagues at the National Cancer Institute discovered an association between the oncometabolite 2-hydroxyglutarate (2-HG) levels, DNA methylation patterns, and breast cancer prognosis.

The authors identified a breast cancer subtype with high levels of 2-HG, and a district DNA methylation pattern that was associated with reduced survival.

This breast cancer subtype was common in African-American breast cancer patients, who as a group have a high prevalence of aggressive breast cancers.

This study indicates that evaluation of 2-HG along with DNA methylation may be a useful biomarker for diagnosis and prognosis


Explore further

Linking risk factors and disease origins in breast cancer

More information: MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis, J Clin Invest. DOI: 10.1172/JCI71180
Citation: Breast cancer prognosis associated with oncometabolite accumulation (2013, December 9) retrieved 26 May 2019 from https://medicalxpress.com/news/2013-12-breast-cancer-prognosis-oncometabolite-accumulation.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more